NCT04122976 - A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described | Biotech Hunter

Enrollment

805

Participants

Timeline

Start Date

January 30, 2020

Primary Completion Date

July 7, 2026

Study Completion Date

October 7, 2026

Conditions

Prostate Cancer

Interventions

DRUG

Darolutamide(Nubeqa, BAY1841788)

The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.

Trial Locations (41)

11042

Integrated Medical Professionals, PLLC, North New Hyde Park

12603

Premier Medical Group of the Hudson Valley, PC, Poughkeepsie

13210

Associated Medical Professional Urology, Syracuse

17601

Keystone Urology Specialists, Lancaster

23462

Urology of Virginia, Virginia Beach

27612

Associated Urologists of NC, Raleigh

27710

Dukes Cancer Intitute Center for Prostate and Urologic Cancers, Durham

32114

Advanced Urology Institute, Daytona Beach

34205

Manatee Medical Research Institute, Bradenton

35209

Urology Centers of Alabama, Homewood

37203

Vanderbilt University Medical Center, Nashville

47130

First Urology, PSC, Jeffersonville

60643

Research by Design, LLC, Chicago

67206

Wichita Urology Group, Wichita

76508

Baylor Scott & White Medical Center - Temple, Temple

78229

Urology San Antonio, San Antonio

80211

The Urology Center of Colorado, Denver

83814

Beacon Cancer Care, Beacon

85704

Arizona Institute of Urology, Tucson

92123

Genesis Comprehensive Prostate Cancer Center, San Diego

98101

University of Washington, Seattle

98405

MultiCare Institute for Research & Innovation, Tacoma

02719

Southcoast Centers for Cancer Care, Fairhaven

07631

New Jersey Urology, Englewood

01106

Oregon Urology Institutue, Springfield

Unknown

Many Locations, Multiple Locations